https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45032 P<.001). Conclusions: Vaxtracker is an effective tool for monitoring AEFIs in the 55 to 61 years age group. Participant response rates were high for both surveys, in both treatment arms and for each method of sending the survey. This study indicates that administration of 23vPPV was well-tolerated in this cohort. Vaxtracker has successfully demonstrated its application in the monitoring of adverse events in near-real time following vaccination in people participating in a national clinical trial.]]> Wed 26 Oct 2022 10:52:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47086 0.05). Similar results were found for IBS subtypes. Higher serum L-arginine concentration had the strongest association with IBS diagnosis, with an odds ratio of 9.03 for those with serum L-arginine at the 75th (84 μmol/L) versus 25th (46 μmol/L) percentile (95% CI: 5.99–13.62). L-arginine had the best discriminative ability with a bias-adjusted area under the receiver operator characteristic curve of 0.859. Conclusions: Higher serum concentrations of L-arginine and endogenous methylarginines are strongly associated with IBS in adults.]]> Wed 14 Dec 2022 09:23:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14963 Wed 11 Apr 2018 17:03:18 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15057 Wed 11 Apr 2018 16:51:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20351 Wed 11 Apr 2018 12:14:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16780 Wed 11 Apr 2018 09:14:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30265 p < 0.001) as well as compared to their own baseline (5.37 ± 0.20 mmol/L vs 5.8 ± 0.09, p < 0.001). Beta cell function, insulin sensitivity and insulin resistance all showed a statistically significant improvement as well. Conclusion: To our knowledge this is the first trial to show an improvement in glucose handling using HOMA parameters in participants with prediabetes. Larger randomized controlled trials are warranted to confirm these findings and to explore clinical endpoints.]]> Wed 06 Apr 2022 14:00:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50159 Wed 05 Jul 2023 15:35:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54542 Tue 27 Feb 2024 20:40:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47053 Tue 13 Dec 2022 15:25:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26789 Tue 01 May 2018 15:44:52 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35998 Thu 17 Mar 2022 14:39:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37057 Thu 17 Feb 2022 09:29:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47210 Thu 15 Dec 2022 17:18:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36636 Thu 09 Dec 2021 11:03:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46986 Thu 06 Jul 2023 15:13:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13951 Sat 24 Mar 2018 10:41:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9648 60 years is growing faster than any other age group and is expected to reach 2 billion worldwide by 2050. Internationally and nationally, considerable efforts are being made to promote active ageing. However, Australia lacks the kind of comprehensive longitudinal research underway in Europe and North America. Although Australia does have a number of longitudinal studies designed to address various issues of health and ageing among older adults, only a few of these studies include a broad and comprehensive range of physical and biological measures. The Hunter Community Study (HCS) is a collaborative study between the University of Newcastle’s School of Medicine and Public Health and the Hunter New England Area Health Service. It is a multi disciplinary initiative that was established to fill some existing gaps in ageing research in Australia and is unique in that it has collected detailed information across all six key policy themes as identified in the Framework for an Australian Ageing Research Agenda.]]> Sat 24 Mar 2018 08:35:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13913 C) and rs5275 (T > C) polymorphisms was performed by real-time polymerase chain reaction using allele-specific probes. Results: Ingestion of any NSAID in the week prior to interview was associated with an elevated risk for ACS: adjusted odds ratio 1.8 (1.2, 2.5). The rs 20417 and rs 5275 polymorphisms were not singly associated with risk for ACS: adjusted odds ratios 1.1 (0.80, 1.5) and 1.2 (0.88, 1.5), respectively. Individually, the polymorphisms did not modify the risk of ACS with the drugs. When analyses were conducted by haplotype, the adjusted odds ratio with celecoxib or rofecoxib in individuals who had one or two copies of the ‘low risk’ haplotype (no GT) was 1.2 (0.29, 5.0), compared with 2.1 (1.1, 4.0) with the ‘high risk’ haplotype (one or two copies of GT). Conclusions: We found little evidence of a gene/drug interaction. We found a statistically non-significant trend toward a lower risk of coronary events with NSAIDs in the presence of the ‘low risk’ haplotype. Even if confirmed, the clinical utility of the finding would be limited as this haplotype is carried by a minority of the population.]]> Sat 24 Mar 2018 08:25:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20501 Sat 24 Mar 2018 07:59:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20897 Sat 24 Mar 2018 07:57:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17876 Sat 24 Mar 2018 07:56:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20622 Sat 24 Mar 2018 07:55:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19175 Sat 24 Mar 2018 07:52:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19394 Sat 24 Mar 2018 07:52:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8539 Mon 23 Sep 2019 11:55:24 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41884 Mon 15 Aug 2022 15:25:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55070 Mon 08 Apr 2024 13:27:57 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47250 Fri 16 Dec 2022 12:29:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52975 Fri 03 Nov 2023 15:30:53 AEDT ]]>